BPCR.LSE BioPharma Credit PLC
- Market cap
- USD 1.09B
- P/E
- 9.7x
- P/B
- 0.96x
- ROE
- 17.7%
- Dividend yield
- 10.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BPCR.LSE undervalued?
Graham numberBPCR.LSE trades 35.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioPharma Credit PLC fundamental analysis
No fundamental analysis for BioPharma Credit PLC yet.
BioPharma Credit PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.
Full company profileBioPharma Credit PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioPharma Credit PLC annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 33.6M | 78.7M | 124M | 91.4M | 88.0M | 184M | 160M | 124M | 140M | 230M |
| Gross Profit | 33.6M | 60.2M | 124M | 91.4M | 88.0M | 184M | 110M | 124M | 115M | 230M |
| Operating Income | 27.1M | 70.1M | 122M | 89.1M | 85.0M | 182M | 108M | 122M | 130M | 202M |
| EBITDA | 27.1M | 74.1M | 122M | 89.1M | 85.0M | 182M | 108M | 122M | 130M | - |
| Net Income | 27.2M | 70.1M | 122M | 89.1M | 85.0M | 182M | 108M | 122M | 130M | 202M |
| EPS | 0.04 | 0.05 | 0.09 | 0.06 | 0.06 | 0.13 | 0.08 | 0.10 | 0.11 | 0.18 |
| Balance Sheet | ||||||||||
| Total Assets | 925M | 1.39B | 1.43B | 1.39B | 1.37B | 1.36B | 1.36B | 1.20B | 1.17B | 1.14B |
| Total Liabilities | 2.92M | 13.3M | 25.2M | 9.39M | 6.90M | 26.3M | 15.9M | 17.9M | 17.6M | 3.23M |
| Shareholders' Equity | 923M | 1.38B | 1.40B | 1.38B | 1.36B | 1.34B | 1.34B | 1.18B | 1.15B | 1.14B |
| Cash & Short-term Investments | 351M | 364M | 297M | 193M | 94.7M | 121M | 135M | 5.62M | 12.6M | 68.7M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 23.1M | 67.1M | 132M | 58.1M | 96.4M | 184M | 123M | 112M | 91.1M | 274M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 23.1M | 67.1M | 132M | 58.1M | 96.4M | 184M | 123M | 112M | 91.1M | 274M |
| Ratios | ||||||||||
| ROE | 2.9% | 5.1% | 8.7% | 6.5% | 6.2% | 13.6% | 8.1% | 10.3% | 11.3% | 17.7% |
| ROA | 2.9% | 5.0% | 8.6% | 6.4% | 6.2% | 13.4% | 8.0% | 10.2% | 11.1% | 17.6% |
| Net Profit Margin | 80.7% | 89.1% | 98.6% | 97.6% | 96.6% | 99.0% | 67.9% | 98.2% | 92.6% | 87.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioPharma Credit PLC dividends
- Dividend yield
- 10.12%
- Forward dividend
- 0.07 USD
- Payout ratio
- 85.0%
- Ex-dividend date
- Oct 8, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 110M | 0.10 | 85.0% |
| 2024 | USD 175M | 0.14 | 143.0% |
| 2023 | USD 89.8M | 0.07 | 82.8% |
| 2022 | USD 157M | 0.11 | 85.9% |
| 2021 | USD 100M | 0.07 | 117.9% |
| 2020 | USD 114M | 0.08 | 127.8% |
| 2019 | USD 98.6M | 0.07 | 80.6% |
| 2018 | USD 74.0M | 0.05 | 105.6% |
| 2017 | USD 6.53M | 0.01 | 24.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BioPharma Credit PLC
- Insiders 6.56%
- Institutions 50.09%
- Public & others 43.35%
- Shares outstanding 1.12B
- Free float 1.12B
BioPharma Credit PLC company profile
- Company name
- BioPharma Credit PLC
- Ticker
- BPCR.LSE
- ISIN
- GB00BDGKMY29
- Exchange
- London Exchange
- Sector
- Financial Services
- Industry
- Capital Markets
- Fiscal year end
- December
- Address
- 51 Lime Street, London, United Kingdom, EC3M 7DQ
- Phone
- 44 13 9247 7500
- Website
- bpcruk.com
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.
BioPharma Credit PLC management
3- Mr. Pedro Gonzalez de CosioInvestment Manager
- Mr. Pablo LegorretaInvestment Manager · born 1963
- Mr. Martin FriedmanInvestment Manager · born 1965